Treatment of central serous chorioretinopathy with beta-blocker metipranolol
Language English Country Czech Republic Media print-electronic
Document type Journal Article, Randomized Controlled Trial
PubMed
23549516
DOI
10.5507/bp.2013.015
Knihovny.cz E-resources
- MeSH
- Administration, Oral MeSH
- Adrenergic beta-Antagonists administration & dosage MeSH
- Central Serous Chorioretinopathy diagnosis drug therapy physiopathology MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Humans MeSH
- Macula Lutea drug effects pathology MeSH
- Metipranolol administration & dosage MeSH
- Follow-Up Studies MeSH
- Tomography, Optical Coherence MeSH
- Prospective Studies MeSH
- Treatment Outcome MeSH
- Dose-Response Relationship, Drug MeSH
- Visual Acuity MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Adrenergic beta-Antagonists MeSH
- Metipranolol MeSH
AIM: The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC). METHODS: A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium. RESULTS: There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341). CONCLUSIONS: In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.
References provided by Crossref.org
